BioTuesdays

Category - Markets

Markets

Piper cuts Intersect ENT to neutral; PT to $17 from $30

Piper Jaffray downgraded Intersect ENT (NASDAQ:XENT) to “neutral” from “overweight” and slashed its price target to $17 from $30 after the company reported second quarter results and lowered its revenue guidance to flat...

August 2, 2019
T2 Biosystems Logo
Markets

AGP cuts T2 Biosystems to neutral; PT 40 cents

Alliance Global Partners downgraded T2 Biosystems (NASDAQ:TTOO) to “neutral” from “buy” with a price target of 40 cents after the company reported second quarter results. The stock closed at 59 cents on Aug. 1. The...

August 2, 2019
Cellectar Biosciences Logo
Markets

Brookline starts Cellectar Biosciences at buy; PT $6

Brookline Capital Markets launched coverage of Cellectar Biosciences (NASDAQ:CLRB) with a “buy” rating and price target of $6. The stock closed at $2.14 on July 29. Cellectar has a unique cancer target delivery platform...

July 30, 2019
Markets

Brookline starts Progenics Pharma at buy; PT $10

Brookline Capital Markets initiated coverage of Progenics Pharmaceuticals (NASDAQ:PGNX) with a “buy” rating and $10 price target. The stock closed at $5.25 on July 29. “We expect that Progenics is well poised to ramp up...

July 30, 2019
Heat Biologics
Markets

Brookline starts Heat Biologics at buy; PT $8

Brookline Capital Markets launched coverage of Heat Biologics (NASDAQ:HTBX) with a “buy” rating and $8 price target. The stock closed at 52 cents on July 29. Heat Biologics has cell-therapy platforms called ImPACT and...

July 30, 2019
Markets

Brookline starts Veru at buy; PT $12

Brookline Capital Markets initiated coverage of Veru (NASDAQ:VERU) with a “buy” rating and $12 price target. The stock closed at $2.23 on July 29. “In our view, VERU-111 and zuclomiphene have potential to be value...

July 30, 2019
KalVista Pharmaceuticals Logo
Markets

SVB Leerink starts Kalvista Pharma at OP; PT $31

SVB Leerink initiated coverage of Kalvista Pharmaceuticals (NASDAQ:KALV) with an “outperform” rating and $31 price target. The stock closed at $16.92 on July 26. Kalvista is creating a new generation of small molecule...

July 29, 2019
Celsion
Markets

Brookline starts Celsion at buy; PT $9

Brookline Capital Markets launched coverage of Celsion (NASDAQ:CLSN) with a “buy” rating and $9 price target. The stock closed at $1.79 on July 25. Celsion is focused on clinical-stage oncology products and platform...

July 26, 2019